Sign Up Today and Learn More About Owkin Stock
Invest in or calculate the value of your shares in Owkin or other pre-IPO companies through EquityZen's platform.
About Owkin Stock
Founded
2016
Headquarters
New York, NY, US
Industries
Software, Artificial Intelligence, Data and Analytics
Owkin is a startup that provides machine learning that allows medical researchers to test AI models on distributed data. The company deploys AI and federated learning for medical research and aims to empower researchers in hospitals, universities, and pharmaceutical companies to understand why drug efficacy varies from patient to patient, enhance the drug development process, and identify the best drug for the right patient to improve treatment outcomes. It is backed by investors such as F-Prime Capital & Eight Roads Ventures, GV, Otium Ventures, Cathay Innovation, and NJF Capital as well as a scientific board. It was co-founded in 2016 by Thomas Clozel, a hematologist oncologist and researcher, and Gilles Wainrib, a computer science teacher-researcher in New York, New York.
Owkin Press Mentions
Stay in the know about the latest news on Owkin
A vision for the hospital of the future
fastcompany • Nov 24, 2024
Systems and methods for detecting tertiary lymphoid structures
patents • Nov 02, 2024
Systems and methods for determining breast cancer prognosis and associated …
patents • Nov 02, 2024
Systems and methods for designing randomized controlled studies
patents • Nov 02, 2024
Systems and methods for image classification
patents • Nov 02, 2024
Investors in Owkin
Discover investors in Owkin stock and explore their portfolio companies
Owkin Management
Leadership team at Owkin
Chief Executive Officer
Thomas Clozel
Join now and verify your accreditation status to gain access to:
- Owkin current valuation
- Owkin stock price
- Available deals in Owkin and all other companies
- Deal offering documents
- EquityZen's proprietary data and insights, including
- Cap tables, which include funding history by Share Class and Liquidity Preferences
- Company Highlights
- Business Model
- Risk Factors
How to invest in Owkin stock?
Accredited investors can buy pre-IPO stock in companies like Owkin through EquityZen funds. These investments are made available by existing Owkin shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Owkin stock?
Shareholders can sell their Owkin stock through EquityZen's private company marketplace. EquityZen's network includes over 330K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 43K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
